News from cognition therapeutics, inc. (cogrx) A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 30, 2016, 08:32 ET Society for Neuroscience 2016 Annual Meeting Nanosymposium Explores Potential of "Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics"

Susan Catalano, Ph.D., founder and CSO of Cognition Therapeutics, Inc., (CogRx) a clinical stage neuroscience company focused on the development of...


Oct 28, 2016, 07:00 ET Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO

Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been appointed President...


Sep 29, 2016, 07:30 ET Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson's Disease

Cognition Therapeutics Inc. (CogRx), a privately held, clinical stage pharmaceutical company focused on discovering and developing disease-modifying...


Nov 12, 2014, 03:00 ET Cognition Therapeutics Inc. Announces Publication of Research Identifying sigma-2/PGRMC1 Receptor as a Major New Drug Target for Alzheimer's Disease Therapy

Cognition Therapeutics Inc. (CogRx) today announced the publication online of two articles entitled: "Alzheimer's therapeutics targeting Amyloid beta ...


May 21, 2014, 03:15 ET Cognition Therapeutics' Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer's Disease Selected for Support by National Institute on Aging/NIH Cooperative Agreement Program

Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying...


Apr 01, 2014, 05:17 ET Cognition Therapeutics, Inc. (CogRx) Receives a US Patent for a Drug to Fight Alzheimer's Disease

Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role...